Skip to search formSkip to main contentSkip to account menu

obeticholic acid

Known as: 6-ethyl-3,7-dihydroxycholan-24-oic acid, 6-ethyl chenodeoxycholic acid, 6?-ethylchenodeoxycholic acid 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Chenodeoxycholic Acid

Narrower (1)

INT 747
analogs & derivativesobeticholic acid 5 MG Oral Tablet [Ocaliva]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism
Review
2018
Review
2018
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
2018
2018
Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
2018
2018
Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.
FXR is a member of the nuclear receptor superfamily, which regulates the expression of various genes involved in bile acid, lipid… 
Review
2018
Review
2018
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives
ABSTRACT Introduction: Farnesoid X nuclear receptor is involved in the regulation of lipid and glucose metabolism, though mainly… 
2018
2018
Evolving role of obeticholic acid in primary biliary cholangitis
Primary biliary cholangitis (PBC) is an immunemediated cholestatic liver disease characterized by destruction of the small… 
Review
2016
Review
2016
 NASH: A glance at the landscape of pharmacological treatment.
 The role of nonalcoholic fatty liver disease, namely nonalcoholic steatohepatitis (NASH), as risk factor for liver- and non… 
2015
2015
Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Although cardiovascular disease and… 
Review
2014
Review
2014
Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies
Chronic inflammatory bile duct diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result… 
2011
2011
OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC
Introduction Obeticholic Acid (OCA), 6-ethyl chenodeoxycholic acid (CDCA) or INT-747, is a novel derivative of the primary human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)